Original Article

You have free access to this content

Race does not impact outcome for advanced ovarian cancer patients treated with cisplatin/paclitaxel†‡

An Analysis of Gynecologic Oncology Group Trials

  1. John H. Farley MD1,¶,*,
  2. Chunqiao Tian MD2,
  3. G. Scott Rose MD3,
  4. Carol L. Brown MD4,
  5. Michael Birrer MD, PhD5,§,
  6. G. Larry Maxwell MD3

Article first published online: 17 JUN 2009

DOI: 10.1002/cncr.24482

Issue

Cancer

Cancer

Volume 115, Issue 18, pages 4210–4217, 15 September 2009

Additional Information

How to Cite

Farley, J. H., Tian, C., Rose, G. S., Brown, C. L., Birrer, M. and Larry Maxwell, G. (2009), Race does not impact outcome for advanced ovarian cancer patients treated with cisplatin/paclitaxel. Cancer, 115: 4210–4217. doi: 10.1002/cncr.24482

Author Information

  1. 1

    Department of Obstetrics and Gynecology, Uniformed Services University of the Health Sciences, Maryland

  2. 2

    Gynecologic Oncology Group Statistical and Data Center, Roswell Park Cancer Institute, Buffalo, New York

  3. 3

    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, and the United States Military Cancer Institute, Walter Reed Army Medical Center, Washington, DC

  4. 4

    Gynecology Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York

  5. 5

    Center for Cancer Research, National Cancer Institute, Bethesda, Maryland

  1. §

    Dr. Michael Birrer's current address is Massachusetts General Hospital, Boston, Massachusetts

  1. Fax: (301)295-0814

*Uniformed Serviced University of Health Sciences, Department of Obstetrics and Gynecology, 4301 Jones Bridge Road, Bethesda, MD 20832

  1. †

    The following Gynecologic Oncology Group member institutions participated in this study: University of Alabama at Birmingham; Duke University Medical Center; Abington Memorial Hospital; University of Rochester Medical Center; Walter Reed Army Medical Center; Wayne State University; University of Minnesota Medical School; Emory University Clinic; University of Mississippi Medical Center; Colorado Gynecologic Oncology Group, P.C.; University of California at Los Angeles; University of Washington; University of Pennsylvania Cancer Center; Milton S. Hershey Medical Center; Georgetown University Hospital; University of Cincinnati; University of North Carolina School of Medicine; University of Texas Southwestern Medical Center at Dallas; Indiana University School of Medicine; Wake Forest University School of Medicine; Albany Medical College; University of California Medical Center at Irvine; Tufts-New England Medical Center; Rush-Presbyterian–St. Luke's Medical Center; State University of New York Downstate Medical Center; University of Kentucky; Community Clinical Oncology Program, the Cleveland Clinic Foundation; Johns Hopkins Oncology Center; State University of New York at Stony Brook; Eastern Pennsylvania GYN/ONC Center, P.C.; Washington University School of Medicine; Cooper Hospital/University Medical Center; Columbus Cancer Council; University of Massachusetts Medical School; Fox Chase Cancer Center; Medical University of South Carolina; Women's Cancer Center, University of Oklahoma; University of Virginia Health Sciences Center; University of Chicago; Tacoma General Hospital, Thomas Jefferson University Hospital; Case Western Reserve University; Tampa Bay Cancer Consortium; North Shore University Hospital; Gynecologic Oncology Network; Oregon Health Sciences University; University of Southern California at Los Angeles; University of Miami School of Medicine; Stanford University Medical Center; Eastern Virginia Medical School; University of Arizona Health Science Center; Mayo Clinic; and Long Island Jewish Medical Center.

  2. ‡

    This article is US Government work and, as such, is in the public domain in the United States of America.

Publication History

  1. Issue published online: 4 SEP 2009
  2. Article first published online: 17 JUN 2009
  3. Manuscript Accepted: 5 FEB 2009
  4. Manuscript Revised: 28 JAN 2009
  5. Manuscript Received: 10 DEC 2008

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (199K)

Cited in:

CrossRef

This article has been cited by:

  1. 1
    LEIGH G. SEAMON, DEBRA L. RICHARDSON, LARRY J. COPELAND, Evolution of the Gynecologic Oncology Group Protocols in the Treatment of Epithelial Ovarian Cancer, Clinical Obstetrics and Gynecology, 2012, 55, 1, 131

    CrossRef

  2. 2
    Mishka Terplan, Nicholas Schluterman, Erica J. McNamara, J. Kathleen Tracy, Sarah M. Temkin, Have racial disparities in ovarian cancer increased over time? An analysis of SEER data, Gynecologic Oncology, 2012, 125, 1, 19

    CrossRef

  3. 3
    Robin A. Laskey, Marek S. Poniewierski, Micael A. Lopez, Rabbie K. Hanna, Angeles Alvarez Secord, Paola A. Gehrig, Gary H. Lyman, Laura J. Havrilesky, Predictors of severe and febrile neutropenia during primary chemotherapy for ovarian cancer, Gynecologic Oncology, 2012, 125, 3, 625

    CrossRef

  4. 4
    Clare Reade, Laurie Elit, Trends in Gynecologic Cancer Care in North America, Obstetrics and Gynecology Clinics of North America, 2012, 39, 2, 107

    CrossRef

  5. 5
    Viet Hong Phan, Cindy Tan, Anneliese Rittau, Hongmei Xu, Andrew J McLachlan, Stephen J Clarke, An update on ethnic differences in drug metabolism and toxicity from anti-cancer drugs, Expert Opinion on Drug Metabolism & Toxicology, 2011, 7, 11, 1395

    CrossRef

  6. 6
    Robert E. Bristow, Stefanie Ueda, Melissa A. Gerardi, Onaopemipo B. Ajiboye, Okechukwu A. Ibeanu, Analysis of racial disparities in stage IIIC epithelial ovarian cancer care and outcomes in a Tertiary Gynecologic Oncology Referral Center, Gynecologic Oncology, 2011, 122, 2, 319

    CrossRef

  7. 7
    Robert E. Bristow, Marianna L. Zahurak, Okechukwu A. Ibeanu, Racial disparities in ovarian cancer surgical care: A population-based analysis, Gynecologic Oncology, 2011, 121, 2, 364

    CrossRef

View Full Article (HTML) Get PDF (199K)